Journal
SEMINARS IN IMMUNOLOGY
Volume 49, Issue -, Pages -Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2020.101437
Keywords
CAR-T cells; T-cell receptor-modified (TCR) cells; Cytolytic T cells (CTLs); Tumor infiltrating T cells (TILs); Adoptive cell therapy; Hematologic malignancies
Categories
Funding
- NIH [R01CA247497, U01CA239258]
- NCI [T32CA071341]
Ask authors/readers for more resources
Cellular therapies have shown increasing promise as a cancer treatment. Encouraging results against hematologic malignancies are paving the way to move into solid tumors. In this review, we will focus on T-cell therapies starting from tumor infiltrating lymphocytes (TILs) to optimized T-cell receptor-modified (TCR) cells and chimeric antigen receptor-modified T cells (CAR-Ts). We will discuss the positive preclinical and clinical findings of these approaches, along with some of the persisting barriers that need to be overcome to improve outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available